JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 53(2019) N 4 p. 586-595; DOI 10.1134/S0026893319040083 Full Text

D.A. Ponkratova1, A.A. Lushnikova1*

Features of the Structure and Expression of NPM and NCL Genes in Cutaneous Melanoma

1Blokhin Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, 115478 Russia

*LAN21@yandex.ru
Received - 2019-02-12; Revised - 2019-03-05; Accepted - 2019-03-07

Malignant cutaneous melanoma (CM) is an extremely aggressive cancer characterized by a high level of metastatic activity and unfavorable prognosis due to a high incidence of relapses, as well as resistance to standard chemotherapy. Cutaneous melanoma accounts for 80% of deaths from malignant skin tumors. Nucleolin/C23 and nucleophosmin/B23, which constitute altogether ~70% of the nucleolus volume, are promising targets for molecular therapy of melanoma. These proteins perform many important functions in the cell, so disruption of the NCL and/or NPM gene structure and abnormal expression of the C23 and B23 proteins they encode, can lead to unlimited cell proliferation and progression of a tumor. Therefore, investigation of the structure and expression of these genes is a topical problem, which is important for understanding the mechanisms of CM carcinogenesis and for the development of new therapeutic approaches. This paper describes new NCL and NPM polymorphisms, as well as the levels of C23 and B23 expression in normal tissues, CM and mucosal melanoma.

cutaneous melanoma, mucosal melanoma, nucleophosmin, B23, NPM, nucleolin, C23, NCL, gene polymorphism, gene expression, carcinogenesis



JMB-FOOTER RAS-JOURNALS